How long does selinesol treatment last? Detailed explanation of individualized treatment plan!

Selinexor (Selinexor), as a targeted therapy drug for relapsed and refractory multiple myeloma and other hematological tumors, its treatment plan is highly individualized. The specific treatment cycle and course of treatment need to be customized based on multiple factors such as the patient's disease type, tolerance, and treatment response.

For patients with multiple myeloma, selinesol is often combined with chemotherapy drugs such as fludarabine or lenalidomide. Generally speaking, the standard treatment regimen is oral selinesol twice a week, with a treatment cycle of 28 days. After two to three months of treatment, doctors will evaluate whether to continue treatment based on the patient's disease response. Some patients may need long-term maintenance treatment to consolidate the curative effect; while some patients may stop taking medication after reaching a certain course of treatment based on improvement of their condition.

During the treatment process, doctors will pay close attention to the patient's response and adjust the dose or course of treatment of selinesol as appropriate. In the early stages of treatment, doctors will pay special attention to the patient's side effects and efficacy, and use this as a basis to decide whether the dosage of the drug needs to be adjusted. For patients with poor tolerance, the dose may be reduced or the treatment interval may be extended; while for patients with significant efficacy, the current treatment regimen may be maintained or even extended treatment courses may be considered.

For patients who respond well to initial treatment, Selinisol may continue to be used as a maintenance treatment drug to delay the recurrence of the disease and improve the patient's quality of life. Maintenance therapy usually uses lower doses, aiming to reduce side effects and improve long-term patient tolerance. The specific treatment plan and course of treatment need to be formulated by the attending physician based on the patient's actual condition.

It is worth noting that the treatment course of selinesol is not static, but will be adjusted in time according to the patient's condition changes, drug resistance and side effects. In addition, the treatment regimen for selinexol will also be different when treating other types of cancer (such as acute myeloid leukemia, lymphoma, etc.). Therefore, patients need to maintain close communication with their doctors, conduct regular examinations, evaluate the efficacy, and adjust the course of treatment as necessary to ensure maximum treatment effects.

xa0

Reference materials:

National Medical Products Administration (NMPA) official website. Seleniso approval information:https://www.nmpa.gov.cn